New Diranersen Data at CTAD Mark Continued Progress Toward Combination Therapies for Alzheimer’s, Says the ADDF

Longer-term results from the Phase 2 CELIA study suggest clinical benefit may build over time NEW YORK, Nov. 18, 2026 /PRNewswire/ — Today at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, Biogen presented new data from the Phase 2 CELIA study of diranersen…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks